Evidence map›Paper›PMID 31875360›Full record

ArticleThoracic cancer2020

EGFR exon 19-deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non-small cell lung cancer.

Linlin Zhang, Barun Pradhan, Lili Guo, Fanlu Meng, Diansheng Zhong

Open access · goldAbstract read
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. The predictive value ofFrontiers in medicine · 2026
    Article
  2. Article
  3. ERCC1/NGFR affects prognosis in basal-like breast cancer.European journal of medical research · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Linlin ZhangDepartment of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China.ORCID 0000-0002-3303-1001
Barun PradhanGenome-Scale Biology Research Program, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Lili GuoTianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China.
Fanlu MengDepartment of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China.
Diansheng ZhongDepartment of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China.
Tianjin Medical University General Hospital · CNUniversity of Helsinki · FI

Funding

National Natural Science Foundation of China 81702267Wujieping Clinical Project Foundation 320.6750.18366
6 · The paper itself

Abstract

backgroundEpidermal growth factor receptor (EGFR) activating mutations are usually associated with DNA damage repair (DDR) deficiency. However, the precise mechanism has remained elusive. In this study, we aimed to investigate whether EGFR exon 19 deletion mutation downstream signals contributed to DDR deficiency by downregulation of excision repair cross-complementation group-1 (ERCC1), a key factor in DDR, expression and function.

methodsWe first measured cell survival, DNA damage (γ-H2AX foci formation) and damage repair (ERCC1 and RAD51 foci formation) ability in response to DNA cross-linking drug in EGFR exon 19 deletion and EGFR wild-type cells separately. We then investigated the involvement of EGFR downstream signals in regulating ERCC1 expression and function in EGFR exon 19 deletion cells as compared with EGFR wild-type ones.

resultsWe observed increased γ-H2AX, but impaired ERCC1 and RAD51 nuclear foci formation in EGFR exon 19 deletion cells as compared with EGFR wild-type ones treated with DNA cross-linker. In addition, we identified that inhibition of EGFR exon 19 deletion signals increased ERCC1 expression, whereas blocked wild-type EGFR signals decreased ERCC1 expression, on both mRNA and protein levels. Furthermore, EGFR exon 19 deletion downstream signals not only inhibited ERCC1 expression but also influenced ERCC1 foci formation in response to DNA cross-linker.

conclusionOur findings indicated that the aberrant EGFR exon 19 deletion signals were not only associated with decreased expression of ERCC1 but were also involved in impaired ERCC1 recruitment in response to DNA cross-link damage, thereby providing us with more evidence for exploring the mechanism of DDR deficiency in EGFR mutant NSCLC.

Indexed as

DNA DamageDNA RepairGene DeletionMutationApoptosisCarcinoma, Non-Small-Cell LungCell ProliferationDNA-Binding ProteinsEndonucleasesErbB ReceptorsExonsHumansLung NeoplasmsTumor Cells, CulturedDNA-Binding ProteinsEGFR protein, humanEndonucleasesErbB ReceptorsERCC1 protein, humanDNA damage repairEGFR exon 19 deletionERCC1non-small cell lung cancer

Identifiers

PMID31875360
PMCPMC6996978
OpenAlexW2998501843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.